Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind ...

Takeda Pharmaceutical offers attractive dividends and has a low price/book ratio, making it appealing despite recent price drops and US policy uncertainties. The company reported strong Q3 ...

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...

Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product ...

Cancer patients, including those on patient assistance programmes, can look forward to some relief on their imported medicines. Medicines from multinational companies including Pembrolizumab (MSD ...

Evox Therapeutics is the second UK biotech to sign a big deal with a pharma giant this week, snaring an $882 million partnership with Takeda for up to five rare disease programmes. The alliance ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Takeda has officially taken over Shire in a deal that could re-establish the trend for mega mergers in big pharma. The merger was approved yesterday in a court hearing in Jersey, where Shire was ...

We're not finding any listings in your area. Change your location or shop Cars.com to see more! Your message was sent. You'll receive a response shortly. Soldiering into Audi’s electric era, the ...

Premium Budget, Economic Survey Highlights: President Droupadi Murmu addresses the joint sitting of both Houses of Parliament ahead of Economic Survey presentation by Finance Minister Nirmala ...

Cal Lutheran School of Management has started a webpage dedicated to showcasing Business School on Rails highlights ...